Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00957996 · ClinicalTrials.gov registry record · Phase 3
Safety Study of IV Peramivir in Hospitalized Subjects With Confirmed or Suspected Influenza
A Phase 3 study, sponsored by BioCryst Pharmaceuticals.
- Completed
- Registry status
- Phase 3
- Development phase
- 234
- Enrollment target
NCT00957996 is a Phase 3 study that has completed, run by BioCryst Pharmaceuticals. The registered enrollment target is 234 participants.
The verdict
NCT00957996, a Phase 3 study, has completed, sponsored by BioCryst Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 234 participants
- Enrollment target
Study Summary
This is a Phase 3, open-label, randomized study of the antiviral activity, safety, and tolerability of intravenous Peramivir in hospitalized subjects with confirmed or suspected influenza infection.
Interventions
- DRUG Peramivir
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 234 participants |
| Start Date | 2009-10 |
| Est. Completion | 2011-08 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00957996
The ClinicalTrials.gov registry entry for NCT00957996 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 234 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is BioCryst Pharmaceuticals, which has 29 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Peramivir is the first listed.
NCT00957996 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00957996 about?
NCT00957996 is a clinical study titled "Safety Study of IV Peramivir in Hospitalized Subjects With Confirmed or Suspected Influenza". This is a Phase 3, open-label, randomized study of the antiviral activity, safety, and tolerability of intravenous Peramivir in hospitalized subjects with confirmed or suspected influenza infection.
What is the current status of trial NCT00957996?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 234 participants. The study started on 2009-10. Estimated completion is 2011-08.
What interventions are being tested in trial NCT00957996?
The interventions under investigation include: Peramivir (DRUG).
Who is sponsoring clinical trial NCT00957996?
This trial is sponsored by BioCryst Pharmaceuticals, which has 29 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.